ERAS — Erasca, Inc.
$14.39+2.49%
Last close: · regular session
After-hours $14.25 -0.97% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ERAS in the TickerWise workspace.
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 103
- Website: https://www.erasca.com
Latest SEC filings for ERAS
Latest ERAS news
- Erasca drops after sacking COO Read article
- Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf Read article
- Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower Read article
- Erasca, Inc. (NASDAQ:ERAS) Stock Has Consensus Target Price of $22.09 Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.